Biotop-report 2014



Yüklə 0,7 Mb.
Pdf görüntüsü
səhifə1/36
tarix17.01.2018
ölçüsü0,7 Mb.
#21089
  1   2   3   4   5   6   7   8   9   ...   36


BioTOP-Report 

2014


Biotech and Pharma in Berlin-Brandenburg


BioTOPics 47 | May 2014 

BioTOP-Report 2014

Editorial

The German Capital Region – Biotechnology and Life Sciences are Ready for the Future 

3

Biotechnology



The Capital Region – New Jobs and New Companies 

4

Pharma



Attractive Location 

14

Glycoscience



Glyco Research for Innovations in Health Industry 

18

Bioelectronics 



The Joint Lab Bioelectronics – A New Platform for the Integration of  Microelectronics into Life Sciences  20

Business Location

Excellent Services for Berlin-Brandenburg 

24

Spotlight on European Business and Internationalization



The Enterprise Europe Network Berlin-Brandenburg 

26

Biotech Parks



The BioCampus Network Berlin-Brandenburg 

34

 



Addresses 39

Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg

Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de

Editor: Volker Erb

Design & Production: webersupiran.berlin

Translation: Kate Abbott · Berlin

Photos/Figures: BioTOP or authors and:  

Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com 

Page 27 adimas/Fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).

Content



3

BioTOPics 47 | May 2014 

BioTOP-Report 2014

Editorial

The German Capital Region – Biotechnology and 

Life Sciences are Ready for the Future

Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications. 

The establishment of  the Berlin Institute of  Health, successful spin-offs and inward investment show that the Ger-

man capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of  Germany!

With its new “Healthcare Industries” master plan, the capital re-

gion is setting the course for the sector’s development until 2018. 

Basic research, innovation, spin-offs and application – in the fu-

ture, these will remain the four pillars that determine the success-

ful implementation of  the cluster strategy in Berlin-Brandenburg.

Biotechnology/pharmaceuticals, medical technology and the 

healthcare industries are the focal areas. In the coming years, 

biotechnology/pharmaceuticals development will feature:

The creation of new translation platforms in basic research, 

clinical research and industrial biotechnology 

Max Planck and Fraunhofer Research, as well as the Helmholtz 

and Leibnitz Institutes, are drivers of  technology transfer and pio-

neers of  innovative technologies and products.

Concentration on therapy development through new system 

medicine strategies

The Max Delbrück Center for Molecular Medicine and Charité – 

Universitätsmedizin Berlin are the umbrella for the new flagship of  

German biomedicine. 

In diagnostics, focus on the development of companion diag-

nostics

Laboratory medicine, applied research, SMEs and the pharma-



ceuticals industry are pooling their activities for therapy optimiza-

tion in personalized medicine.

In regenerative medicine, concentration on the development of 

new cell therapies

The Berlin-Brandenburg Center for Regenerative Therapies 

(BCRT), biotechnology SMEs and pharmaceuticals partners in 

the international Regenerative Medicine Coalition are part of  a 

high-performance product development network. 

Focus on the sustainable use of biological resources for medi-

cal applications in industrial biotechnology

The Leibniz Institute for Agricultural Engineering, university-related 

research and biotechnology SMEs are successfully implementing 

the federal government’s bioeconomics strategy and contributing 

to the strength of  the healthcare industries.

Development of new growth fields in the life sciences with inter-

disciplinary technologies

Cross innovation at the interface of  microsystems technology, mi-

croelectronics, photonics and surface engineering and thin films 

open up completely new opportunities for analytics, automation 

and hardware development and along with this, for growth, value 

creation and cost reduction.

Value chain expansion via inward investment and industrial 

location expansion

With more than 200 biotechnology companies, over 30 research 

institutions and over 130 clinics and hospitals, Berlin-Branden-

burg is already a European hot spot for the life sciences. Growth 

in expertise, players and investment will reinforce the capital re-

gion’s leading position in the international markets. 

This new edition of  the BioTOP Report provides you with an ex-

citing, informative overview of  the development in the capital re-

gion’s industries. With themes such as glyco-engineering technol-

ogy and bioelectronics, it underscores internationally outstanding 

activities. We wish you reading pleasure and invite you to commit 

to Berlin-Brandenburg as a place to develop your business.

Reach out and contact us! 

Prof. Dr. Peter Seeberger 

Dr. Günter Peine

Expert Circle Spokesman 

Head of  

“Biotech/Pharma“ 

BioTOP Berlin-Brandenburg



Yüklə 0,7 Mb.

Dostları ilə paylaş:
  1   2   3   4   5   6   7   8   9   ...   36




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©www.genderi.org 2024
rəhbərliyinə müraciət

    Ana səhifə